
A respiratory syncytial virus (RSV) vaccine has just been approved for use in pregnant people that protects against dangerous infection in newborns.
On Monday (Aug. 21), the Food and Drug Administration (FDA) announced the approval of Abrysvo, a vaccine made by Pfizer, for use in pregnant individuals. The shot had already been cleared for use in people ages 60 and up, but now, it can also be given in the third trimester of pregnancy, specifically between weeks 32 and 36 of gestation.